Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 1/7/96. \ Origin: Appendix \ 5. \ Amended \ 1/7/98, \ 1/9/99, \ 1/7/2000, \ 30/9/2001, \ 11/3/2002, \ 1/1/2003, \ 24/10/2005.$

ABN 79 11	8 715 772			
We	We (the entity) give ASX the following information.			
_	t 1 - All issues nust complete the relevant sections (attac	ch sheets if there is not enough space).		
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary shares		
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	8,899,994		
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares		

Name of entity

HEALTHZONE LIMITED

24/10/2005 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

equally in the securities rank equally in all respects with existing ordinary shares

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

Total consideration \$2,669,998

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

- Development of proprietary health products
- Brand and business acquisitions
- Working capital
- Costs

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

19 April 2010

8 Number and *class of all *securities quoted on ASX (*including* the securities in clause 2 if applicable)

Number	+Class
65,322,626	Ordinary shares

Appendix 3B Page 2 24/10/2005

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	3,789,766	Warrants
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		
Part	2 - Bonus issue or pro r	ata issue	
11	Is security holder approval required?	NA	
12	Is the issue renounceable or non-renounceable?	NA	
13	Ratio in which the *securities will be offered	NA	
14	⁺ Class of ⁺ securities to which the offer relates	NA	
15	⁺ Record date to determine entitlements	NA	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	NA	
17	Policy for deciding entitlements in relation to fractions	NA	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	NA	
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations	NA	

1/1/2003 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	NA
21	Amount of any underwriting fee or commission	NA
22	Names of any brokers to the issue	NA
23	Fee or commission payable to the broker to the issue	NA
24	Amount of any handling fee	NA
·	payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	NA
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	NA
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	NA
28	Date rights trading will begin (if applicable)	NA
29	Date rights trading will end (if applicable)	NA
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	NA
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	NA

Appendix 3B Page 4 1/1/2003

⁺ See chapter 19 for defined terms.

32	How do *security holders dispose of their entitlements (except by sale through a broker)?	NA
	+D . 1 1 .	
33	⁺ Despatch date	NA
Dant	2 Overtation of accomition	_
	3 - Quotation of securitied only complete this section if you are a	
34	Type of securities (tick one)	
(a)	Securities described in Part	1
(b)	•	end of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that have ticked box 34(a)	
Addi	ional securities forming a nev	v class of securities
Tick to docum	indicate you are providing the informatents	tion or
35		ty securities, the names of the 20 largest holders of and the number and percentage of additional lders
36		y securities, a distribution schedule of the additional number of holders in the categories
37	A copy of any trust deed for	the additional *securities
37	A copy of any trust deed for	the additional *securities

1/1/2003 Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which ⁺ quotation is sought	NA	
39	Class of *securities for which quotation is sought	NA	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest	NA	
	 payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	NA	
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number NA	+Class

Appendix 3B Page 6 1/1/2003

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 19 April 2010

Michaelfer

(Director)

Print name: Michael Jenkins == == == ==

24/10/2005 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.